Sick Sinus Syndrome (SND)

Categories: Cardiovascular diseases, Genetic diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Sick Sinus Syndrome

MalaCards integrated aliases for Sick Sinus Syndrome:

Name: Sick Sinus Syndrome 12 25 37 55 6 44 15 72 33
Sinus Node Dysfunction 25 72
Sinus Node Disease 25 6
Sinus Node Infection 12
Sss 25
Snd 25


External Ids:

Disease Ontology 12 DOID:13884
KEGG 37 H00729
MeSH 44 D012804
NCIt 50 C62244
SNOMED-CT 68 36083008
ICD10 33 I49.5
UMLS 72 C0037052 C0428908

Summaries for Sick Sinus Syndrome

Genetics Home Reference : 25 Sick sinus syndrome (also known as sinus node dysfunction) is a group of related heart conditions that can affect how the heart beats. "Sick sinus" refers to the sino-atrial (SA) node, which is an area of specialized cells in the heart that functions as a natural pacemaker. The SA node generates electrical impulses that start each heartbeat. These signals travel from the SA node to the rest of the heart, signaling the heart (cardiac) muscle to contract and pump blood. In people with sick sinus syndrome, the SA node does not function normally. In some cases, it does not produce the right signals to trigger a regular heartbeat. In others, abnormalities disrupt the electrical impulses and prevent them from reaching the rest of the heart. Sick sinus syndrome tends to cause the heartbeat to be too slow (bradycardia), although occasionally the heartbeat is too fast (tachycardia). In some cases, the heartbeat rapidly switches from being too fast to being too slow, a condition known as tachycardia-bradycardia syndrome. Symptoms related to abnormal heartbeats can include dizziness, light-headedness, fainting (syncope), a sensation of fluttering or pounding in the chest (palpitations), and confusion or memory problems. During exercise, many affected individuals experience chest pain, difficulty breathing, or excessive tiredness (fatigue). Once symptoms of sick sinus syndrome appear, they usually worsen with time. However, some people with the condition never experience any related health problems. Sick sinus syndrome occurs most commonly in older adults, although it can be diagnosed in people of any age. The condition increases the risk of several life-threatening problems involving the heart and blood vessels. These include a heart rhythm abnormality called atrial fibrillation, heart failure, cardiac arrest, and stroke.

MalaCards based summary : Sick Sinus Syndrome, also known as sinus node dysfunction, is related to familial sick sinus syndrome and sinoatrial node disease. An important gene associated with Sick Sinus Syndrome is SCN5A (Sodium Voltage-Gated Channel Alpha Subunit 5), and among its related pathways/superpathways are Cardiac conduction and DREAM Repression and Dynorphin Expression. The drugs Propafenone and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and atrioventricular node, and related phenotypes are behavior/neurological and cardiovascular system

KEGG : 37
Sick sinus syndrome (SSS) comprises a variety of conditions involving sinus node dysfunction and commonly affects elderly persons. Patients may experience syncope, pre-syncope, palpitations, or dizziness. SSS has multiple manifestations on electrocardiogram, including sinus bradycardia, sinus arrest, sinoatrial block, and alternating patterns of bradycardia and tachycardia. Autosomal recessive type (SSS1) can be caused by compound heterozygous mutation in the SCN5A gene, and autosomal dominant type (SSS2) can be caused by heterozygous mutation in the HCN4. SCN5A encodes an alpha-subunit of the cardiac sodium channel carrying the current to form a rapid upstroke of action potential, whereas HCN4 codes for an alpha-subunit of hyperpolarization-activated cation channel.

Wikipedia : 75 Sick sinus syndrome (SSS), is a group of abnormal heart rhythms (arrhythmias) presumably caused by a... more...

Related Diseases for Sick Sinus Syndrome

Diseases in the Sick Sinus Syndrome family:

Sick Sinus Syndrome 2 Sick Sinus Syndrome 1
Sick Sinus Syndrome 3 Familial Sick Sinus Syndrome

Diseases related to Sick Sinus Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 familial sick sinus syndrome 34.4 SCN5A MYH6 HCN4
2 sinoatrial node disease 31.5 SCN5A MYH6 HCN4
3 syncope 31.2 TTN SCN5A
4 atrioventricular block 31.1 SCN5A LMNA HCN4
5 atrial fibrillation 30.7 SCN5A HCN4 F2
6 cardiac conduction defect 30.7 SCN5A LMNA
7 third-degree atrioventricular block 30.4 SCN5A HCN4
8 ventricular fibrillation, paroxysmal familial, 1 30.2 SCN5A CACNA1C
9 right bundle branch block 30.2 SCN5A HCN4 CACNA1C
10 second-degree atrioventricular block 30.1 LMNA HCN4
11 atrial heart septal defect 29.8 MYH6 F2
12 long qt syndrome 2 29.8 SNTA1 SCN5A
13 cardiac arrhythmia 29.7 SCN5A RANGRF CACNA1C
14 familial isolated dilated cardiomyopathy 29.6 TTN SCN5A MYH6
15 atrial standstill 1 29.6 TTN SCN5A MYH6 LMNA
16 cardiomyopathy, dilated, 1e 29.3 TTN SCN5A LMNA
17 arrhythmogenic right ventricular cardiomyopathy 29.2 TTN SCN5A LMNA HCN4
18 long qt syndrome 29.1 SNTA1 SCN5A HCN4 CACNA1C
19 brugada syndrome 28.5 SNTA1 SCN5A SCN10A RANGRF HCN4 CACNA1C
20 muscular disease 28.4 TTN SNTA1 MYH6 LMNA HCN4
21 hypertrophic cardiomyopathy 28.3 TTN SCN5A MYH6 LMNA CACNA1C
22 left ventricular noncompaction 28.0 TTN SNTA1 SCN5A MYH6 LMNA HCN4
23 dilated cardiomyopathy 28.0 TTN SCN5A MYH6 LMNA CACNA1C
24 heart disease 27.0 TTN SCN5A MYH6 LMNA HCN4 F2
25 sick sinus syndrome 1 12.9
26 sick sinus syndrome 3 12.9
27 sick sinus syndrome 2 12.9
28 obsolete: sinus node disease-myopia syndrome 12.4
29 stiff skin syndrome 11.7
30 chronic atrial and intestinal dysrhythmia 11.7
31 isolated levocardia 11.7
32 subclavian steal syndrome 11.5
33 sinus node disease and myopia 11.4
34 cardiac arrhythmia, ankyrin-b-related 11.4
35 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 11.3
36 hypoparathyroidism-retardation-dysmorphism syndrome 11.2
37 hypoparathyroidism-intellectual disability-dysmorphism syndrome 11.2
38 spastic paraplegia, intellectual disability, nystagmus, and obesity 10.5
39 congestive heart failure 10.5
40 progressive familial heart block, type ia 10.4
41 progressive familial heart block, type ib 10.4
42 amyloidosis 10.4
43 long qt syndrome 12 10.3 SNTA1 SCN5A
44 coronary heart disease 1 10.3
45 cardiac arrest 10.3
46 striatonigral degeneration 10.3
47 heart septal defect 10.3
48 cerebrovascular disease 10.3
49 resting heart rate, variation in 10.2
50 heart valve disease 10.2

Graphical network of the top 20 diseases related to Sick Sinus Syndrome:

Diseases related to Sick Sinus Syndrome

Symptoms & Phenotypes for Sick Sinus Syndrome

MGI Mouse Phenotypes related to Sick Sinus Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 CACNA1C F2 LMNA MYH6 SCN10A SCN5A
2 cardiovascular system MP:0005385 9.92 CACNA1C F2 HCN4 LMNA MYH6 SCN10A
3 homeostasis/metabolism MP:0005376 9.86 CACNA1C F2 LMNA MYH6 SCN10A SGO1
4 mortality/aging MP:0010768 9.76 CACNA1C F2 HCN4 LMNA MYH6 SCN5A
5 muscle MP:0005369 9.5 CACNA1C HCN4 LMNA MYH6 SCN5A SNTA1
6 nervous system MP:0003631 9.17 CACNA1C F2 HCN4 LMNA SCN10A SCN5A

Drugs & Therapeutics for Sick Sinus Syndrome

Drugs for Sick Sinus Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Propafenone Approved Phase 4 54063-53-5 4932
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
Ethanol Approved Phase 4 64-17-5 702
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
Atenolol Approved Phase 4 29122-68-7 2249
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Bisoprolol Approved Phase 4 66722-44-9 2405
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Ticagrelor Approved Phase 4 274693-27-5 9871419
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
16 Angiotensinogen Phase 4
17 Giapreza Phase 4
18 Angiotensin II Type 1 Receptor Blockers Phase 4
19 Angiotensin Receptor Antagonists Phase 4
20 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
21 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
22 Cytochrome P-450 CYP3A Inhibitors Phase 4
23 Potassium Channel Blockers Phase 4
24 Natriuretic Agents Phase 4
25 diuretics Phase 4
26 Sodium Chloride Symporter Inhibitors Phase 4
27 Adrenergic Agonists Phase 4
28 Adrenergic beta-Agonists Phase 4
29 Vasodilator Agents Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Hydrocortisone 17-butyrate 21-propionate Phase 4
32 Hydrocortisone hemisuccinate Phase 4
33 Hydrocortisone-17-butyrate Phase 4
34 Analgesics Phase 4
35 Cyclooxygenase Inhibitors Phase 4
36 Analgesics, Non-Narcotic Phase 4
37 Fibrinolytic Agents Phase 4
38 Purinergic P2 Receptor Antagonists Phase 4
39 Purinergic P2Y Receptor Antagonists Phase 4
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4
41 Antipyretics Phase 4
42 Platelet Aggregation Inhibitors Phase 4
43 Antirheumatic Agents Phase 4
44 Albuterol Phase 4
45 Respiratory System Agents Phase 4
46 Adrenergic beta-2 Receptor Agonists Phase 4
47 Tocolytic Agents Phase 4
48 Anti-Asthmatic Agents Phase 4
49 Bronchodilator Agents Phase 4
50 Adrenergic beta-Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
2 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
3 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
4 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
5 Prevention of Atrial Arrhythmia in Patients Without AV Conduction Disease Completed NCT01170611 Phase 4
6 Falls and Cardiovascular Events in Elderly Patients With Sinus Node Disease Treated With a MVPTM Pacemaker According to the ESC 2007 Guidelines Completed NCT01037426 Phase 4
7 Spontaneous Atrio Ventricular Conduction Preservation Completed NCT00655213 Phase 4
8 A Randomized, Prospective Multicenter Study to Examine the Optimal Position of the Atrial Leads for Therapy of the Sinus Node Syndrome Completed NCT00161538 Phase 4
9 The Impact of Heart Rate on Central Hemodynamics in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker Completed NCT03245996 Phase 4 Atenolol Pill;Nebivolol Pill;Ivabradine Pill
10 Analyse Der Unterschiede Zwischen Aktiv-fixierenden Und Passiv-fixierenden Stimulations-Elektroden Hinsichtlich Implantationsdauer Und Elektrischer Parameter Completed NCT00180557 Phase 4
11 Investigational New Drug Application/ Investigational Device Exemption Information Completed NCT00239226 Phase 4
12 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
13 CLEAR: Cylos Pacemaker Responds With Physiologic Rate Changes During Daily Activities Completed NCT00355797 Phase 4
14 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
15 Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease Completed NCT02383771 Phase 4 Ticagrelor;Aspirin + Ticagrelor;Control;Aspirin + Ticagrelor
16 The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial Completed NCT02914652 Phase 4 Salbutamol;Norflouran (Placebo Evohaler(R) )
17 Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE Recruiting NCT03566667 Phase 4 Metoprolol;Standard care
18 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
19 VIRTUE: Virtual Clinic Pacemaker Follow-up Terminated NCT00475124 Phase 4
20 Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling in Patients With Hypertension, Permanent Pacemakers and Risk Factors for Developing Atrial Fibrillation Unknown status NCT00225667 Phase 3 Irbesartan
21 Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study Unknown status NCT02909166 Phase 3 aliskiren
22 Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care. Unknown status NCT02764619 Phase 3 Spironolactone;Placebo
23 Mode Selection Trial in Sinus Node Dysfunction (MOST) Completed NCT00000561 Phase 3
24 Increasing Atrial Base Rate Pacing to Reduce Atrial Fibrillation Completed NCT02317068 Phase 3
25 A Prospective Canadian Multi-Center Randomized Study; Spontaneous AtrioVEntricular Conduction PReservation Completed NCT01219621 Phase 3
26 Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem Completed NCT00319982 Phase 2, Phase 3 Diltiazem;Placebo
27 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
28 Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients Recruiting NCT02809131 Phase 3 polymixin/bacitracin;cephalexin, or levofloxacin, or clindamycin;Saline
29 A Randomized Trial of Closed Loop Stimulation After Epicardial Pacemaker Implantation for Congenital Heart Disease Not yet recruiting NCT03361189 Phase 2, Phase 3
30 The Danish Multicenter Randomised Study on AAI Versus DDD Pacing in Sick Sinus Syndrome Terminated NCT00236158 Phase 2, Phase 3
31 Second Study on Cardio-neuromodulation in Humans Unknown status NCT02954666 Phase 2
32 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
33 Minimizing Right Ventricular Pacing in Dual-chamber Pacemaker Patients With Sinus Node Disease and First Degree Atrioventricular Block. Unknown status NCT01611389
34 Identification of Gene Polymorphism in Patients With Sick Sinus Syndrome in Chinese Population in Taiwan Unknown status NCT00314223
35 The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome Unknown status NCT01310920
36 The Effect of Losartan on Atrial Fibrillation and Pacemaker Dependence in Sick Sinus Syndrome (SSS) Patients Receiving Physiological Pacemaker - A Prospective, Randomized, Multicenter Study in Taiwan Unknown status NCT00647257 Losartan;Placebo
37 Left Ventricular Function and Remodelling During Permanent Pacing Unknown status NCT00228241
38 Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia Unknown status NCT01310907
39 Comparison of Right Ventricular Septal Pacing to Minimized Right Ventricular Septal Stimulation in Patients With Sick Sinus Syndrome Unknown status NCT01477138
40 Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance Unknown status NCT01798043
41 Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study Unknown status NCT02314897
42 Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position - Right Pace Study Unknown status NCT01647490
43 A Trial Comparing the Sensitivity and Specificity of Coronary Angiography With Coronary CT Angiography Unknown status NCT00146887
44 Perioperative Administration of COX 2 Inhibitors and Beta Blockers in Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence Unknown status NCT00502684 Propranolol, etodolac
45 INGEVITY(TM) Active Fixation and Passive Fixation Pace/ Sense Lead Clinical Study Completed NCT01688843
46 Clinical Observations of Automatic Algorithms for Cardiac Pacing Completed NCT00286858
47 Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction (SAVE PACe) Completed NCT00284830
48 A Comparison of Rate Response Performance in Pacemaker Patients With an Indication of Sinus Node Dysfunction. Completed NCT02027909
49 Ingenio Device Algorithm Study Completed NCT01441583
50 AV-Hysteresis Versus Mode Switch to AAI (MVP) for the Avoidance of Unnecessary Right Ventricular Pacing Completed NCT01803217

Search NIH Clinical Center for Sick Sinus Syndrome

Cochrane evidence based reviews: sick sinus syndrome

Genetic Tests for Sick Sinus Syndrome

Anatomical Context for Sick Sinus Syndrome

MalaCards organs/tissues related to Sick Sinus Syndrome:

Heart, Testes, Atrioventricular Node, Brain, Endothelial, Breast, Lung

Publications for Sick Sinus Syndrome

Articles related to Sick Sinus Syndrome:

(show top 50) (show all 3382)
# Title Authors PMID Year
The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. 38 71
18451998 2008
Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. 71
10377081 1999
Sick sinus syndrome, progressive cardiac conduction disease, atrial flutter and ventricular tachycardia caused by a novel SCN5A mutation. 9 38
20395683 2010
Cardiac sodium channel Na(v)1.5 and interacting proteins: Physiology and pathophysiology. 9 38
19744495 2010
Mouse models of SCN5A-related cardiac arrhythmias. 9 38
19041666 2008
A novel C-terminal truncation SCN5A mutation from a patient with sick sinus syndrome, conduction disorder and ventricular tachycardia. 9 38
17897635 2007
Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). 9 38
14523039 2003
[An intrapatient comparison of adaptation to aerobic and anaerobic exertion during 3 types of physiological cardiac stimulation in chronotropic failure of the sinus node: DDD, VVIR and DDDR]. 9 38
9118155 1997
[Secretion of atrial natriuretic peptide during artificial pacing: assessments including the influence of ventriculoatrial conduction]. 9 38
1307573 1992
Efficacy of cilostazol for sick sinus syndrome to avoid permanent pacemaker implantation: A retrospective case-control study. 38
30982679 2019
Risk of cardiac arrhythmias in patients with chronic hepatitis B and C infections - A 13-year nationwide population-based study. 38
30982681 2019
MicroRNA-1976 regulates degeneration of the sinoatrial node by targeting Cav1.2 and Cav1.3 ion channels. 38
31302118 2019
Initial experience with transcatheter pacemaker implantation for adults with congenital heart disease. 38
31045294 2019
Post-pacemaker implant QRS duration and heart failure admission in patients with sick sinus syndrome and complete atrioventricular block. 38
31111655 2019
Trastuzumab-Induced Cardiomyopathy and Intermittent Left Bundle Branch Block. 38
31413780 2019
Dual Sinus Nodes With Donor Sinus Node Dysfunction in Biatrial Heart Transplantation. 38
31107496 2019
Nkx2-5 defines a subpopulation of pacemaker cells and is essential for the physiological function of the sinoatrial node in mice. 38
31320323 2019
Importance of Finding Embolic Sources for Patients with Embolic Stroke of Undetermined Source. 38
31097326 2019
Muscle weakness and impaired motor coordination in Hcn1-deficient rats. 38
31292305 2019
Pacing-induced cardiomyopathy in chronic right ventricular apical pacing: a midterm follow-up study. 38
31331388 2019
Glucocorticoid-Sensitive Paroxysmal Atrial Fibrillation, Sick Sinus Syndrome, and Mitral Regurgitation in a Patient with Malignant Rheumatoid Vasculitis. 38
31292399 2019
Pacemaker treatment after Fontan surgery-A Swedish national study. 38
30883035 2019
Surgical Outcomes of Permanent Epicardial Pacing in Neonates and Young Infants Less Than 1 Year of Age. 38
30064922 2019
Etiology of tricuspid valve disease is a predictor of bradyarrhythmia after tricuspid valve surgery. 38
30938919 2019
Challenges in Bradicardias Interpretation. 38
31084850 2019
A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation. 38
31350002 2019
Clinical characteristics and rhythm outcome of catheter ablation of hemodynamically corrected valvular atrial fibrillation. 38
30850308 2019
Slow and steady or fast and furious? Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia. 38
31231896 2019
Subpectoral pacemaker implantation under tumescent local analgesia. 38
31214327 2019
Heart Failure Differentially Modulates Natural (Sinoatrial Node) and Ectopic (Pulmonary Veins) Pacemakers: Mechanism and Therapeutic Implication for Atrial Fibrillation. 38
31262061 2019
Marijuana Induced Sick Sinus Syndrome: A Case Report. 38
31227686 2019
Cardiac Rhythm Disturbances in Heterotaxy Syndrome. 38
30877320 2019
Identification of a novel exon3 deletion of RYR2 in a family with catecholaminergic polymorphic ventricular tachycardia. 38
30615235 2019
Fetal arrhythmias: Diagnosis and management. 38
30817991 2019
Leadless pacemaker implantation: A feasible and reasonable option in transcatheter heart valve replacement patients. 38
30829416 2019
Bradycardia secondary to primary hyperparathyroidism. 38
30971152 2019
[Mycobacterium Mageritense Bacteremia after Implantation of Pacemaker;Report of a Case]. 38
31268041 2019
Prospective evaluation of feasibility, electrophysiologic and echocardiographic characteristics of left bundle branch area pacing. 38
31136869 2019
Bradyarrhythmias in Arrhythmogenic Right Ventricular Cardiomyopathy. 38
30885416 2019
Recent understanding of clinical sequencing and gene-based risk stratification in inherited primary arrhythmia syndrome. 38
30910390 2019
Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. 38
31125667 2019
A new combination of transcription factors increases the harvesting efficiency of pacemaker‑like cells. 38
30864738 2019
Enhanced closed-state inactivation of mutant cardiac sodium channels (SCN5A N1541D and R1632C) through different mechanisms. 38
30935997 2019
Permanent pacemaker implantation after pediatric heart transplantation: Risk factors, indications, and outcomes. 38
30790343 2019
Atrial fibrillation occurring during head-up tilt testing: Once detected, atrial fibrillation should be monitored, regardless of how it is detected. 38
30528450 2019
Superior vena cava syndrome due to pacemaker leads: an Indian report with a review of management practices. 38
30968668 2019
A 45-year experience with the Fontan procedure: tachyarrhythmia, an important sign for adverse outcome. 38
31038168 2019
Sinus node dysfunction in patients with Fontan circulation: could heart rate variability be a predictor for pacemaker implantation? 38
30918992 2019
Mutant KCNJ3 and KCNJ5 Potassium Channels as Novel Molecular Targets in Bradyarrhythmias and Atrial Fibrillation. 38
30764634 2019
A sexy approach to pacemaking: differences in function and molecular make up of the sinoatrial node. 38
30968943 2019

Variations for Sick Sinus Syndrome

ClinVar genetic disease variations for Sick Sinus Syndrome:

6 (show top 50) (show all 112)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SCN5A NM_000335.4(SCN5A): c.3890C> T (p.Pro1297Leu) single nucleotide variant Pathogenic rs28937319 3:38603976-38603976 3:38562485-38562485
2 SCN5A NM_000335.4(SCN5A): c.5347G> A (p.Glu1783Lys) single nucleotide variant Pathogenic/Likely pathogenic rs137854601 3:38592513-38592513 3:38551022-38551022
3 SCN5A NM_000335.4(SCN5A): c.1252G> T (p.Glu418Ter) single nucleotide variant Likely pathogenic rs869025519 3:38647528-38647528 3:38606037-38606037
4 SCN5A NM_000335.4(SCN5A): c.5451C> T (p.Ala1817=) single nucleotide variant Conflicting interpretations of pathogenicity rs370114378 3:38592409-38592409 3:38550918-38550918
5 SCN5A NM_000335.4(SCN5A): c.2259C> T (p.Asn753=) single nucleotide variant Conflicting interpretations of pathogenicity rs878911306 3:38639223-38639223 3:38597732-38597732
6 SCN5A NM_000335.4(SCN5A): c.2181C> T (p.Ile727=) single nucleotide variant Conflicting interpretations of pathogenicity rs186942072 3:38639301-38639301 3:38597810-38597810
7 SCN5A NM_000335.4(SCN5A): c.687T> C (p.Thr229=) single nucleotide variant Conflicting interpretations of pathogenicity rs770390440 3:38655250-38655250 3:38613759-38613759
8 SCN5A NM_000335.4(SCN5A): c.3360G> A (p.Ala1120=) single nucleotide variant Conflicting interpretations of pathogenicity rs9858585 3:38620852-38620852 3:38579361-38579361
9 SCN5A NM_000335.4(SCN5A): c.2436+12G> A single nucleotide variant Conflicting interpretations of pathogenicity rs41312419 3:38628879-38628879 3:38587388-38587388
10 SCN5A NM_000335.4(SCN5A): c.4434+13C> T single nucleotide variant Conflicting interpretations of pathogenicity rs148598985 3:38597919-38597919 3:38556428-38556428
11 SCN5A NM_000335.4(SCN5A): c.21T> A (p.Pro7=) single nucleotide variant Conflicting interpretations of pathogenicity rs587781157 3:38674778-38674778 3:38633287-38633287
12 SCN5A NM_000335.4(SCN5A): c.1044C> T (p.Pro348=) single nucleotide variant Conflicting interpretations of pathogenicity rs370346797 3:38648256-38648256 3:38606765-38606765
13 SCN5A NM_000335.4(SCN5A): c.1743G> A (p.Ser581=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313687 3:38645350-38645350 3:38603859-38603859
14 SCN5A NM_000335.4(SCN5A): c.2437-5C> A single nucleotide variant Conflicting interpretations of pathogenicity rs72549411 3:38627537-38627537 3:38586046-38586046
15 SCN5A NM_000335.4(SCN5A): c.3870G> A (p.Leu1290=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313033 3:38603996-38603996 3:38562505-38562505
16 SCN5A NM_000335.4(SCN5A): c.6000C> T (p.Leu2000=) single nucleotide variant Conflicting interpretations of pathogenicity rs538707712 3:38591860-38591860 3:38550369-38550369
17 SCN5A NM_000335.4(SCN5A): c.1068T> C (p.Asp356=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313703 3:38648232-38648232 3:38606741-38606741
18 SCN5A NM_000335.4(SCN5A): c.3388-7T> C single nucleotide variant Conflicting interpretations of pathogenicity rs41310769 3:38618279-38618279 3:38576788-38576788
19 SCN5A NM_000335.4(SCN5A): c.1800G> A (p.Val600=) single nucleotide variant Conflicting interpretations of pathogenicity rs758101066 3:38645293-38645293 3:38603802-38603802
20 SCN5A NM_000335.4(SCN5A): c.2151G> A (p.Pro717=) single nucleotide variant Conflicting interpretations of pathogenicity rs191840835 3:38639331-38639331 3:38597840-38597840
21 SCN5A NM_000335.4(SCN5A): c.1681C> T (p.Leu561=) single nucleotide variant Conflicting interpretations of pathogenicity rs45522138 3:38645412-38645412 3:38603921-38603921
22 SCN5A NM_000335.4(SCN5A): c.3228+6C> G single nucleotide variant Conflicting interpretations of pathogenicity rs368048551 3:38622416-38622416 3:38580925-38580925
23 SCN5A NM_000335.4(SCN5A): c.5604C> T (p.Asp1868=) single nucleotide variant Conflicting interpretations of pathogenicity rs560476223 3:38592256-38592256 3:38550765-38550765
24 SCN5A NM_000335.4(SCN5A): c.4821C> T (p.Leu1607=) single nucleotide variant Conflicting interpretations of pathogenicity rs45437099 3:38593039-38593039 3:38551548-38551548
25 SCN5A NM_000335.4(SCN5A): c.1569T> A (p.Arg523=) single nucleotide variant Conflicting interpretations of pathogenicity rs41313693 3:38645524-38645524 3:38604033-38604033
26 HCN4 NM_005477.3(HCN4): c.3498_3501TTTG[1] (p.Phe1168fs) short repeat Uncertain significance rs786205259 15:73614933-73614936 15:73322592-73322595
27 SNTA1 NM_003098.2(SNTA1): c.388T> C (p.Phe130Leu) single nucleotide variant Uncertain significance rs199964677 20:32026755-32026755 20:33438949-33438949
28 SCN5A NM_000335.4(SCN5A): c.*1390A> G single nucleotide variant Uncertain significance rs41310753 3:38590422-38590422 3:38548931-38548931
29 SCN5A NM_000335.4(SCN5A): c.*1705C> T single nucleotide variant Uncertain significance rs886058440 3:38590107-38590107 3:38548616-38548616
30 SCN5A NM_000335.4(SCN5A): c.*1943C> A single nucleotide variant Uncertain significance rs569552176 3:38589869-38589869 3:38548378-38548378
31 SCN5A NM_000335.4(SCN5A): c.5283C> T (p.Ile1761=) single nucleotide variant Uncertain significance rs375323548 3:38592577-38592577 3:38551086-38551086
32 SCN5A NM_000335.4(SCN5A): c.*290G> A single nucleotide variant Uncertain significance rs886058457 3:38591522-38591522 3:38550031-38550031
33 SCN5A NM_000335.4(SCN5A): c.*889C> A single nucleotide variant Uncertain significance rs546849670 3:38590923-38590923 3:38549432-38549432
34 SCN5A NM_000335.4(SCN5A): c.*1164G> T single nucleotide variant Uncertain significance rs41315489 3:38590648-38590648 3:38549157-38549157
35 SCN5A NM_000335.4(SCN5A): c.*1673C> T single nucleotide variant Uncertain significance rs886058443 3:38590139-38590139 3:38548648-38548648
36 SCN5A NM_000335.4(SCN5A): c.*1932C> T single nucleotide variant Uncertain significance rs886058437 3:38589880-38589880 3:38548389-38548389
37 SCN5A NM_000335.4(SCN5A): c.-70C> T single nucleotide variant Uncertain significance rs886058465 3:38691039-38691039 3:38649548-38649548
38 SCN5A NM_000335.4(SCN5A): c.1870C> A (p.Leu624Ile) single nucleotide variant Uncertain significance rs886058463 3:38645223-38645223 3:38603732-38603732
39 SCN5A NM_000335.4(SCN5A): c.*160G> A single nucleotide variant Uncertain significance rs772585696 3:38591652-38591652 3:38550161-38550161
40 SCN5A NM_000335.4(SCN5A): c.6030C> A (p.Asp2010Glu) single nucleotide variant Uncertain significance rs886058459 3:38591830-38591830 3:38550339-38550339
41 SCN5A NM_000335.4(SCN5A): c.*2135C> A single nucleotide variant Uncertain significance rs45502793 3:38589677-38589677 3:38548186-38548186
42 SCN5A NM_000335.4(SCN5A): c.*1969C> T single nucleotide variant Uncertain significance rs190416544 3:38589843-38589843 3:38548352-38548352
43 SCN5A NM_000335.4(SCN5A): c.*1731G> C single nucleotide variant Uncertain significance rs569249327 3:38590081-38590081 3:38548590-38548590
44 SCN5A NM_000335.4(SCN5A): c.*1496T> G single nucleotide variant Uncertain significance rs41313015 3:38590316-38590316 3:38548825-38548825
45 SCN5A NM_000335.4(SCN5A): c.*1443C> A single nucleotide variant Uncertain significance rs886058445 3:38590369-38590369 3:38548878-38548878
46 SCN5A NM_000335.4(SCN5A): c.*1087G> A single nucleotide variant Uncertain significance rs886058446 3:38590725-38590725 3:38549234-38549234
47 SCN5A NM_000335.4(SCN5A): c.*1074C> G single nucleotide variant Uncertain significance rs776171341 3:38590738-38590738 3:38549247-38549247
48 SCN5A NM_000335.4(SCN5A): c.*705C> A single nucleotide variant Uncertain significance rs886058452 3:38591107-38591107 3:38549616-38549616
49 SCN5A NM_000335.4(SCN5A): c.*663C> A single nucleotide variant Uncertain significance rs540984871 3:38591149-38591149 3:38549658-38549658
50 SCN5A NM_000335.4(SCN5A): c.*516G> T single nucleotide variant Uncertain significance rs886058454 3:38591296-38591296 3:38549805-38549805

Expression for Sick Sinus Syndrome

Search GEO for disease gene expression data for Sick Sinus Syndrome.

Pathways for Sick Sinus Syndrome

Pathways related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
4 11.13 SCN5A MYH6
Show member pathways
6 10.8 SCN5A SCN10A

GO Terms for Sick Sinus Syndrome

Cellular components related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intercalated disc GO:0014704 9.26 SCN5A RANGRF
2 voltage-gated sodium channel complex GO:0001518 9.16 SCN5A SCN10A
3 sarcolemma GO:0042383 9.13 SNTA1 SCN5A CACNA1C
4 Z disc GO:0030018 8.92 TTN SCN5A MYH6 CACNA1C

Biological processes related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.94 SCN5A SCN10A HCN4 CACNA1C
2 transmembrane transport GO:0055085 9.93 SCN5A SCN10A HCN4 CACNA1C
3 ion transmembrane transport GO:0034220 9.83 SCN5A SCN10A CACNA1C
4 sodium ion transport GO:0006814 9.78 SCN5A SCN10A HCN4
5 sodium ion transmembrane transport GO:0035725 9.71 SCN5A SCN10A HCN4
6 regulation of ion transmembrane transport GO:0034765 9.67 SCN5A SCN10A HCN4 CACNA1C
7 sarcomere organization GO:0045214 9.65 TTN MYH6
8 muscle filament sliding GO:0030049 9.64 TTN MYH6
9 neuronal action potential GO:0019228 9.63 SCN5A SCN10A
10 cardiac muscle contraction GO:0060048 9.63 TTN SCN5A MYH6
11 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.62 SNTA1 SCN5A
12 regulation of cardiac muscle contraction GO:0055117 9.62 SCN10A HCN4
13 ventricular cardiac muscle cell action potential GO:0086005 9.61 SNTA1 SCN5A
14 striated muscle contraction GO:0006941 9.6 TTN MYH6
15 membrane depolarization during action potential GO:0086010 9.59 SCN5A SCN10A
16 cardiac muscle fiber development GO:0048739 9.58 TTN MYH6
17 cardiac muscle cell action potential involved in contraction GO:0086002 9.58 SCN5A CACNA1C
18 regulation of heart rate by cardiac conduction GO:0086091 9.58 SCN5A HCN4 CACNA1C
19 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.57 SCN5A SCN10A
20 regulation of membrane depolarization GO:0003254 9.56 RANGRF HCN4
21 muscle contraction GO:0006936 9.56 TTN SNTA1 MYH6 HCN4
22 regulation of cardiac muscle cell action potential involved in regulation of contraction GO:0098909 9.55 RANGRF HCN4
23 SA node cell action potential GO:0086015 9.52 SCN5A HCN4
24 membrane depolarization during SA node cell action potential GO:0086046 9.51 SCN5A HCN4
25 membrane depolarization during AV node cell action potential GO:0086045 9.49 SCN5A CACNA1C
26 AV node cell action potential GO:0086016 9.48 SCN5A SCN10A
27 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.43 SCN5A CACNA1C
28 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.33 SCN5A HCN4 CACNA1C
29 bundle of His cell action potential GO:0086043 9.32 SCN5A SCN10A
30 regulation of sodium ion transmembrane transport GO:1902305 9.13 SNTA1 SCN5A RANGRF
31 regulation of heart rate GO:0002027 9.1 SNTA1 SCN5A SCN10A RANGRF MYH6 HCN4

Molecular functions related to Sick Sinus Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.67 SCN5A SCN10A HCN4 CACNA1C
2 ion channel binding GO:0044325 9.56 SNTA1 SCN5A SCN10A RANGRF
3 sodium channel activity GO:0005272 9.5 SCN5A SCN10A HCN4
4 voltage-gated ion channel activity GO:0005244 9.46 SCN5A SCN10A HCN4 CACNA1C
5 sodium channel regulator activity GO:0017080 9.43 SNTA1 RANGRF
6 nitric-oxide synthase binding GO:0050998 9.4 SNTA1 SCN5A
7 voltage-gated sodium channel activity GO:0005248 9.13 SCN5A SCN10A HCN4
8 calmodulin binding GO:0005516 9.02 TTN SNTA1 SCN5A MYH6 CACNA1C

Sources for Sick Sinus Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....